Skip Navigation

Europace 2005 7(3):227-230; doi:10.1016/j.eupc.2004.12.012
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (3)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Kilickap, S.
Right arrow Articles by Barista, I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kilickap, S.
Right arrow Articles by Barista, I.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2005 The European Society of Cardiology. Published by Elsevier Ltd. All rights reserved.

CASE REPORT

Doxorubicin-induced second degree and complete atrioventricular block

Saadettin Kilickap*, Ebru Akgul, Sercan Aksoy, Kudret Aytemir and Ibrahim Barista

Hacettepe University Oncology Institute, Medical Oncology Department, Hacettepe University Faculty of Medicine, Cardiology Department Sihhiye 06100 Ankara, Turkey

Doxorubicin is one of the most effective chemotherapeutic agents used in the treatment of malignancies. Cardiotoxicity is the most important dose-limiting toxicity of doxorubicin. Although cardiomyopathy is the most well known side effect of doxorubicin, it usually occurs many years after the treatment and relates to cumulative doxorubicin dosage. Another form of doxorubicin cardiotoxicity is arrhythmia which may occur at any time and after any dosage. However, doxorubicin-induced arrhythmia is rarely a life-threatening side effect. In this report, we present a case in which there were doxorubicin-induced life-threatening arrhythmias.

Key Words: doxorubicin, cardiotoxicity, arrhythmia

*Corresponding author. Tel.: C90 312 305 2937; fax: C90 312 309 2905. E-mail address: skilickap{at}yahoo.com (S. Kilickap).


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 EuropaceHome page
M. Guglin, M. Aljayeh, S. Saiyad, R. Ali, and A. B. Curtis
Introducing a new entity: chemotherapy-induced arrhythmia
Europace, December 1, 2009; 11(12): 1579 - 1586.
[Abstract] [Full Text] [PDF]

Home page
 EuropaceHome page
T. Rudzinski, M. Ciesielczyk, W. Religa, Z. Bednarkiewicz, and M. Krzeminska-Pakula
Doxorubicin-induced ventricular arrhythmia treated by implantation of an automatic cardioverter-defibrillator
Europace, May 1, 2007; 9(5): 278 - 280.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.